Recent Advances in Targeted Therapies

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across targeted therapies. Few important targeted therapy innovations have been presented along with summary of clinical trials for CAR T 19 and CTL019 therapies. The focus of the TOE is on disease screening and management. The corresponding clinical trials scenario is also depicted along with the industry interactions. In particular, clinical trial analysis and industry interactions around CRISPR/Cas-9 gene editing are highlighted.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer

Table of Contents

Recent Advances in Targeted TherapiesInnovations Across the Targeted Therapy LandscapeFirst-in-class CAR-T-Cell Therapy Garners US FDA ApprovalActemra (Tocilizumab) Receives US FDA Approval for CAR T-cell-induced Cytokine Release Syndrome (CRS) Antibody Therapeutics for the Management of FibrosisDimension Therapeutics to be Acquired by REGENXBIOClinical Trial Analysis and Industry InteractionsSummary of Clinical Trials for CAR T 19 and CTL019 TherapiesSummary of Key Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.